Polatuzumab vedotin: Revision history

From IDWiki

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

18 August 2025

  • curprev 15:4615:46, 18 August 2025 Aidan talk contribs 639 bytes +639 Created page with "* Anti-CD79b antibody with a humanized IgG1 monoclonal antibody and monomethyl auristatin E (MMAE, an antimitotic agent) * Indicated for diffuse large B-cell lymphoma * Adverse effects ** Include rash, anorexia, diarrhea, nausea/vomiting, fatigue, myelosuppression and opportunistic infections ** Infusion reactions can occur as late as 24 hours post-infusion ** Tumour lysis syndrome ** Hepatotoxicity, mostly low-grade and reversible ** Serious infections, includin..." Tag: Visual edit
Retrieved from "https://idwiki.org/Polatuzumab_vedotin"
Powered by MediaWiki
Powered by Semantic MediaWiki